Ketamine in the Past, Present, and Future: Mechanisms, Metabolites, and Toxicity
Eric S. Schwenka b✉, Basant Pradhanc, Rohit Nalamasud, Lucas Stollee, Irving W. Wainerf, Michael Cirullog, Alexander Olsonb, Joseph V. Pergolizzie, Marc C. Torjmanb, Eugene R. Viscusib
- aDepartment of Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University, 111 South 11th Street, Gibbon Building, 8290, Philadelphia, PA, 19107, USA. Eric.Schwenk@jefferson.edu
- bDepartment of Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University, 111 South 11th Street, Gibbon Building, 8290, Philadelphia, PA, 19107, USA
- cPsychiatry & Pediatrics, Cooper Medical School of Rowan University, Camden, NJ, USA
- dDepartment of Physical Medicine and Rehabilitation, University of Nebraska Medical Center, Omaha, NE, USA
- eNEMA Research, Inc., Naples, FL, USA
- fCooper Medical School, Rowan University, Camden, NJ, USA
- gDepartment of Anesthesiology, Thomas Jefferson University Hospital, Philadelphia, PA, USA
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Purpose of review: While ketamine's analgesia has mostly been attributed to antagonism of N-methyl-D-aspartate receptors, evidence suggests multiple other pathways are involved in its antidepressant and possibly analgesic activity. These mechanisms and ketamine's role in the nociplastic pain paradigm are discussed. Animal studies demonstrating ketamine's neurotoxicity have unclear human translatability and findings from key rodent and human studies are presented. Recent findings: Ketamine's metabolites, and (2R,6R)-hydroxynorketamine in particular, may play a greater role in its clinical activity than previously believed. The activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and the mammalian target of rapamycin by ketamine are mechanisms that are still being elucidated. Ketamine might work best in nociplastic pain, which involves altered pain processing. While much is known about ketamine, new studies will continue to define its role in clinical medicine. Evidence supporting ketamine's neurotoxicity in humans is lacking and should not impede future ketamine clinical trials.
TL;DRKetamine’s metabolites, and (2R,6R)-hydroxynorketamine in particular, may play a greater role in its clinical activity than previously believed and might work best in nociplastic pain, which involves altered pain processing. (Semantic Scholar)